+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application, Type (Innovative, Generic), Type of Manufacturer (Inhouse, Outsourced), Route of Administration, Synthesis Technology, and Region with Growth Forecasts, 2025-2030- Product Image
Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application, Type (Innovative, Generic), Type of Manufacturer (Inhouse, Outsourced), Route of Administration, Synthesis Technology, and Region with Growth Forecasts, 2025-2030- Product Image
New

Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application, Type (Innovative, Generic), Type of Manufacturer (Inhouse, Outsourced), Route of Administration, Synthesis Technology, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 153 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5831009
Description Jump to:
The Peptide Therapeutics Market was valued at USD 117.26 billion in 2024, and is projected to reach USD 260.25 billion by 2030, rising at a CAGR of 10.77%. It is expected to grow at a CAGR of 10.77% from 2025 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights

  • By type, the generic segment is the second largest segment in the market. The rise of generic peptide therapeutics is an emerging trend in the pharmaceutical industry
  • Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
  • Based on synthesis technology, the recombinant DNA technology segment accounted for the largest revenue share of 79.26% in 2024
  • The North America Peptide Therapeutics market maintains a leading position in 2024 with share of 60.21% globally in 2024, driven by the rising prevalence of cancer, metabolic disorders, and rare diseases

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Increasing prevalence of cancer
3.3.1.1.1. Cancer incidence data
3.3.1.2. Technological advancements
3.3.1.3. Presence of strong product pipeline
3.3.2. Market Restraints Analysis
3.3.2.1. Increasing complexity of peptides
3.3.2.2. High cost of manufacturing equipment
3.4. Peptide Therapeutics Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
3.6. Phase 3 Pipeline Drug Forecasts
3.7. Case Studies Analysis
Chapter 4. Peptide Therapeutics Market: By Application Estimates & Trend Analysis
4.1. Peptide Therapeutics Market: Application Segment Dashboard
4.2. Peptide Therapeutics Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
4.3. Metabolic Disorders
4.3.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Cancer
4.4.1. Cancer Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Neurological Disorders
4.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Gastrointestinal Disorders
4.6.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Cardiovascular Disorders
4.7.1. Cardiovascular Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.8. Pain
4.8.1. Pain Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.9. Infectious Disease
4.9.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.10. Renal Disorders
4.10.1. Renal Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.11. Dermatological Disorders
4.11.1. Dermatological Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.12. Respiratory Disorders
4.12.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.13. Others
4.13.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Peptide Therapeutics Market: Type Estimates & Trend Analysis
5.1. Peptide Therapeutics Market: Type Segment Dashboard
5.2. Peptide Therapeutics Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
5.3. Innovative
5.3.1. Innovative Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.4. Generic
5.4.1. Generic Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.4.2. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis
6.1. Peptide Therapeutics Market: Type of Manufacturer Segment Dashboard
6.2. Peptide Therapeutics Market: By Type of Manufacturer Movement Analysis, 2024 & 2030 (USD Million)
6.3. Inhouse
6.3.1. Inhouse Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Outsourced
6.4.1. Outsourced Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis
7.1. Peptide Therapeutics Market: Synthesis Technology Segment Dashboard
7.2. Peptide Therapeutics Market: Synthesis Technology Movement Analysis, 2024 & 2030 (USD Million)
7.3. Recombinant DNA Technology
7.3.1. Recombinant DNA Technology Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
7.4. Solid-Phase Peptide Synthesis (SPPS)
7.4.1. Solid-Phase Peptide Synthesis (SPPS) Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Hybrid
7.5.1. Hybrid Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Liquid-Phase Peptide Synthesis (LPPS)
7.6.1. Liquid-Phase Peptide Synthesis (LPPS) Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Others
7.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis
8.1. Peptide Therapeutics Market: Route of Administration Segment Dashboard
8.2. Peptide Therapeutics Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
8.3. Parenteral Route
8.3.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
8.4. Oral Route
8.4.1. Oral Route Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Mucosal
8.5.1. Mucosal Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
8.6. Pulmonary
8.6.1. Pulmonary Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
8.7. Others
8.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis
9.1. Peptide Therapeutics Market Share, by Region, 2024 & 2030, USD Million
9.2. North America
9.2.1. North America Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Regulatory Framework
9.2.2.4. Reimbursement Framework
9.2.2.5. U.S. Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Regulatory Framework
9.2.3.4. Reimbursement Framework
9.2.3.5. Canada Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.2.4. Mexico
9.2.4.1. Key Country Dynamics
9.2.4.2. Target Disease Prevalence
9.2.4.3. Regulatory Framework
9.2.4.4. Reimbursement Framework
9.2.4.5. Mexico Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3. Europe
9.3.1. Europe Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Regulatory Framework
9.3.2.4. Reimbursement Framework
9.3.2.5. Uk Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Regulatory Framework
9.3.3.4. Reimbursement Framework
9.3.3.5. Germany Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Regulatory Framework
9.3.4.4. Reimbursement Framework
9.3.4.5. France Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Regulatory Framework
9.3.5.4. Reimbursement Framework
9.3.5.5. Italy Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Regulatory Framework
9.3.6.4. Reimbursement Framework
9.3.6.5. Spain Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Regulatory Framework
9.3.7.4. Reimbursement Framework
9.3.7.5. Denmark Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Regulatory Framework
9.3.8.4. Reimbursement Framework
9.3.8.5. Sweden Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Regulatory Framework
9.3.9.4. Reimbursement Framework
9.3.9.5. Norway Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Regulatory Framework
9.4.2.4. Reimbursement Framework
9.4.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Regulatory Framework
9.4.3.4. Reimbursement Framework
9.4.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Regulatory Framework
9.4.4.4. Reimbursement Framework
9.4.4.5. India Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4.5. Australia
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Regulatory Framework
9.4.5.4. Reimbursement Framework
9.4.5.5. Australia Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4.6. South Korea
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Regulatory Framework
9.4.6.4. Reimbursement Framework
9.4.6.5. South Korea Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Regulatory Framework
9.4.7.4. Reimbursement Framework
9.4.7.5. Thailand Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.5. Latin America
9.5.1. Latin America Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Regulatory Framework
9.5.2.4. Reimbursement Framework
9.5.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.5.3. Argentina
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Regulatory Framework
9.5.3.4. Reimbursement Framework
9.5.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.6. Middle East and Africa
9.6.1. Middle East and Africa Peptide Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Regulatory Framework
9.6.2.4. Reimbursement Framework
9.6.2.5. South Africa Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Regulatory Framework
9.6.3.4. Reimbursement Framework
9.6.3.5. Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Regulatory Framework
9.6.4.4. Reimbursement Framework
9.6.4.5. UAE Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Regulatory Framework
9.6.5.4. Reimbursement Framework
9.6.5.5. Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis by Key Market Participants
10.2. Company Categorization
10.3. Participant Overview
10.4. Financial Performance
10.5. Product Bench Marking
10.6. Company Market Share Analysis, 2024
10.7. Company Profiles
10.7.1. Eli Lilly and Company
10.7.1.1. Participant’s Overview
10.7.1.2. Financial Performance
10.7.1.3. Product Benchmarking
10.7.1.4. Recent Developments/ Strategic Initiatives
10.7.2. Pfizer Inc.
10.7.2.1. Participant’s Overview
10.7.2.2. Financial Performance
10.7.2.3. Product Benchmarking
10.7.2.4. Recent Developments/ Strategic Initiatives
10.7.3. Amgen Inc.
10.7.3.1. Participant’s Overview
10.7.3.2. Financial Performance
10.7.3.3. Product Benchmarking
10.7.3.4. Recent Developments/ Strategic Initiatives
10.7.4. Takeda Pharmaceutical Company Limited
10.7.4.1. Participant’s Overview
10.7.4.2. Financial Performance
10.7.4.3. Product Benchmarking
10.7.4.4. Recent Developments/ Strategic Initiatives
10.7.5. AstraZeneca
10.7.5.1. Participant’s Overview
10.7.5.2. Financial Performance
10.7.5.3. Product Benchmarking
10.7.5.4. Recent Developments/ Strategic Initiatives
10.7.6. Teva Pharmaceutical Industries Ltd.
10.7.6.1. Participant’s Overview
10.7.6.2. Financial Performance
10.7.6.3. Product Benchmarking
10.7.6.4. Recent Developments/ Strategic Initiatives
10.7.7. Sanofi
10.7.7.1. Participant’s Overview
10.7.7.2. Financial Performance
10.7.7.3. Product Benchmarking
10.7.7.4. Recent Developments/ Strategic Initiatives
10.7.8. F. Hoffmann-La Roche Ltd
10.7.8.1. Participant’s Overview
10.7.8.2. Financial Performance
10.7.8.3. Product Benchmarking
10.7.8.4. Recent Developments/ Strategic Initiatives
10.7.9. Novartis AG
10.7.9.1. Participant’s Overview
10.7.9.2. Financial Performance
10.7.9.3. Product Benchmarking
10.7.9.4. Recent Developments/ Strategic Initiatives
10.7.10. Novo Nordisk A/S
10.7.10.1. Participant’s Overview
10.7.10.2. Financial Performance
10.7.10.3. Product Benchmarking
10.7.10.4. Recent Developments/ Strategic Initiatives
10.7.11. GSK plc
10.7.11.1. Participant’s Over
10.7.11.2. Financial Performance
10.7.11.3. Product Benchmarking
10.7.11.4. Recent Developments/ Strategic Initiatives
10.7.12. Ironwood Pharmaceuticals, Inc.
10.7.12.1. Participant’s Overview
10.7.12.2. Financial Performance
10.7.12.3. Product Benchmarking
10.7.12.4. Recent Developments/ Strategic Initiatives
10.7.13. Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
10.7.13.1. Participant’s Overview
10.7.13.2. Financial Performance
10.7.13.3. Product Benchmarking
10.7.13.4. Recent Developments/ Strategic Initiatives
10.7.14. Ipsen Pharma
10.7.14.1. Participant’s Overview
10.7.14.2. Financial Performance
10.7.14.3. Product Benchmarking
10.7.14.4. Recent Developments/ Strategic Initiatives
Chapter 11. Conclusion/Key Takeaways/KoL Insights
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 North America peptide therapeutics market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 4 North America peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 5 North America peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 6 North America peptide therapeutics market estimates and forecasts, by type of manufacturer, 2018-2030 (USD Million)
Table 7 North America peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 8 North America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 9 U.S. peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 10 U.S. peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 11 U.S. peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 12 U.S. peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 13 U.S. peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 14 Canada peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 15 Canada peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 16 Canada peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 17 Canada peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 18 Canada peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 19 Mexico peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 20 Mexico peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 21 Mexico peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 22 Mexico peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 23 Mexico peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 24 Europe peptide therapeutics market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 25 Europe peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 26 Europe peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 27 Europe peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 28 Europe peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 29 Europe peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 30 UK peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 31 UK peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 32 UK peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 33 UK peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 34 UK peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 35 Germany peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 36 Germany peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 37 Germany peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 38 Germany peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 39 Germany peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 40 France peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 41 France peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 42 France peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 43 France peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 44 France peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 45 Spain peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 46 Spain peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 47 Spain peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 48 Spain peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 49 Spain peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 50 Italy peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 51 Italy peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 52 Italy peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 53 Italy peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 54 Italy peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 55 Denmark peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 56 Denmark peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 57 Denmark peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 58 Denmark peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 59 Denmark peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 60 Sweden peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 61 Sweden peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 62 Sweden peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 63 Sweden peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 64 Sweden peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 65 Norway peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 66 Norway peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 67 Norway peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 68 Norway peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 69 Norway peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 70 Asia Pacific peptide therapeutics market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 71 Asia Pacific peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 72 Asia Pacific peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 73 Asia Pacific peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 74 Asia Pacific peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 75 Asia Pacific peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 76 Japan peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 77 Japan peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 78 Japan peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 79 Japan peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 80 Japan peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 81 China peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 82 China peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 83 China peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 84 China peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 85 China peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 86 India peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 87 India peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 88 India peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 89 India peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 90 India peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 91 South Korea peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 92 South Korea peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 93 South Korea peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 94 South Korea peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 95 South Korea peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 96 Australia peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 97 Australia peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 98 Australia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 99 Australia peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 100 Australia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 101 Thailand peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 102 Thailand peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 103 Thailand peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 104 Thailand peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 105 Thailand peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 106 Latin America peptide therapeutics market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 107 Latin America peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 108 Latin America peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 109 Latin America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 110 Latin America peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 111 Latin America peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 112 Brazil peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 113 Brazil peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 114 Argentina peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 115 Argentina peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 116 Argentina peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 117 Argentina peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 118 Argentina peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 119 MEA peptide therapeutics market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 120 MEA peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 121 MEA peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 122 MEA peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 123 MEA peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 124 MEA peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 125 South Africa peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 126 South Africa peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 127 South Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 128 South Africa peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 129 South Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 130 UAE peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 131 UAE peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 132 UAE peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 133 UAE peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 134 UAE peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 135 Saudi Arabia peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 136 Saudi Arabia peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 137 Saudi Arabia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 138 Saudi Arabia peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 139 Saudi Arabia peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 140 Kuwait peptide therapeutics market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 141 Kuwait peptide therapeutics market estimates and forecasts, by type, 2018-2030 (USD Million)
Table 142 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 143 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 144 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
Table 145 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2018-2030 (USD Million)
Table 146 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 147 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2018-2030 (USD Million)
List of Figures
Figure 1 Peptide therapeutics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain-based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Application segment snapshot
Figure 10 Type and type of manufacturers segment snapshot
Figure 11 Route of administration and synthesis technology segment snapshot
Figure 12 Competitive landscape snapshot
Figure 13 Pharmaceutical market, (USD Billion)
Figure 14 Market dynamics
Figure 15 The most common cancers globally are listed in the table below
Figure 16 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
Figure 17 The figure below shows the phase of therapeutic peptides in clinical trials
Figure 18 Porter’s five forces analysis
Figure 19 PESTLE analysis
Figure 20 Peptide therapeutics market: Application outlook and key takeaways
Figure 21 Peptide therapeutics market: Application movement analysis
Figure 22 Cancer market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Metabolic disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Cardiovascular disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Respiratory disorders market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Gastrointestinal disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Infectious diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Pain market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Dermatological disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Neurological disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 31 Renal disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Peptide therapeutics market: Type outlook and key takeaways
Figure 34 Peptide therapeutics market: Type movement analysis
Figure 35 Generic market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Innovative market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Peptide therapeutics market: Type of manufacturers outlook and key takeaways
Figure 38 Peptide therapeutics market: Type of manufacturers movement analysis
Figure 39 In-house market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Outsourced market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Peptide therapeutics market: Route of administration outlook and key takeaways
Figure 42 Peptide therapeutics market: Route of administration movement analysis
Figure 43 Parenteral route market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Oral route market estimates and forecast, 2018-2030 (USD Million)
Figure 45 Pulmonary market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Mucosal market estimates and forecast, 2018-2030 (USD Million)
Figure 47 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 48 Peptide therapeutics market: Synthesis technology outlook and key takeaways
Figure 49 Peptide therapeutics market: Synthesis technology movement analysis
Figure 50 Solid Phase Peptide Synthesis (SPPS) market estimates and Forecast, 2018-2030 (USD Million)
Figure 51 Recombinant DNA technology market estimates and forecast, 2018-2030 (USD Million)
Figure 52 Hybrid technology market estimates and forecast, 2018-2030 (USD Million)
Figure 53 Liquid-Phase Peptide Synthesis (LPPS) technology market estimates and forecast, 2018-2030 (USD Million)
Figure 54 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 55 Peptide therapeutics market revenue, by region, 2024 & 2030, (USD Million)
Figure 56 Regional marketplace: Key takeaways
Figure 57 Regional marketplace: Key takeaways
Figure 58 North America peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 59 Key country dynamics
Figure 60 Target disease prevalence
Figure 61 U.S. peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 62 Key country dynamics
Figure 63 Target disease prevalence
Figure 64 Canada peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Mexico peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Key country dynamics
Figure 67 Target disease prevalence
Figure 68 Europe peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 Key country dynamics
Figure 70 Target disease prevalence
Figure 71 UK peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 Key country dynamics
Figure 73 Target disease prevalence
Figure 74 Germany peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Key country dynamics
Figure 76 Target disease prevalence
Figure 77 France peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 78 Key country dynamics
Figure 79 Target disease prevalence
Figure 80 Spain peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Key country dynamics
Figure 82 Target disease prevalence
Figure 83 Italy peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Target disease prevalence
Figure 86 Denmark peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Key country dynamics
Figure 88 Target disease prevalence
Figure 89 Sweden peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Key country dynamics
Figure 91 Target disease prevalence
Figure 92 Norway peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Rest of Europe peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 94 Asia Pacific peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 Key country dynamics
Figure 96 Target disease prevalence
Figure 97 Japan peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 98 Key country dynamics
Figure 99 Target disease prevalence
Figure 100 China peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Key country dynamics
Figure 102 Target disease prevalence
Figure 103 India peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 104 Key country dynamics
Figure 105 Target disease prevalence
Figure 106 Australia peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 107 Key country dynamics
Figure 108 Thailand peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 109 Key country dynamics
Figure 110 South Korea peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 111 Rest of Asia Pacific peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 112 Latin America peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 113 Key country dynamics
Figure 114 Target disease prevalence
Figure 115 Brazil peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 116 Key country dynamics
Figure 117 Target disease prevalence
Figure 118 Argentina peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 119 Rest of Latin America peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 120 MEA peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 121 Key country dynamics
Figure 122 Target disease prevalence
Figure 123 South Africa peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 124 Key country dynamics
Figure 125 Target disease prevalence
Figure 126 Saudi Arabia peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 127 Key country dynamics
Figure 128 Target disease prevalence
Figure 129 UAE peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 130 Key country dynamics
Figure 131 Target disease prevalence
Figure 132 Kuwait peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 133 Rest of MEA peptide therapeutics market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

The major companies profiled in this Peptide Therapeutics market report include:
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Novo Nordisk A/S
  • GSK plc
  • Ironwood Pharmaceuticals, Inc.
  • Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
  • Ipsen Pharma

Methodology

Loading
LOADING...

Related Topics

Related Reports

Peptide Therapeutics Market by Technology, Drug Class, Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2025-2030 - Product Image

Peptide Therapeutics Market by Technology, Drug Class, Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Peptide Therapeutics Market Report by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region 2024-2032 - Product Image

Peptide Therapeutics Market Report by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Peptide Therapeutics Market Report 2025 - Product Image

Peptide Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Peptide Therapeutics - Global Strategic Business Report - Product Image

Peptide Therapeutics - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.